. . . . . . "Humans and other mammals"@en . "Vapreotide"@en . . . "30 minutes"@en . . . . . . . . . . " "@en . . "The exact mechanism of action is unknown, although one study has provided in vitro and in vivo evidence for a tachykinin NK1 receptor antagonist effect in the analgesic effects of vapreotide (PMID: 7556407)."@en . . . . . . "Vapreotide is 76% eliminated in bile. The remainder is renally eliminated."@en . . "For the treatment of esophageal variceal bleeding in patients with cirrhotic liver disease and has also shown efficacy in the treatment of patients with AIDS-related diarrhea."@en . "approved"@en . "Safety data are limited, however, headache, fatigue, diarrhea, nausea, vomiting, and abdominal pain have been reported commonly with the use of vapreotide."@en . . "# Sarr MG: The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial. J Am Coll Surg. 2003 Apr;196(4):556-64; discussion 564-5; author reply 565. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12691930 # Vapreotide: BMY 41606, RC 160, Sanvar. Drugs R D. 2003;4(5):326-30. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12952505 # Norman P: Vapreotide (Debipharm). IDrugs. 2000 Nov;3(11):1358-72. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16047258 # Betoin F, Ardid D, Herbet A, Aumaitre O, Kemeny JL, Duchene-Marullaz P, Lavarenne J, Eschalier A: Evidence for a central long-lasting antinociceptive effect of vapreotide, an analog of somatostatin, involving an opioidergic mechanism. J Pharmacol Exp Ther. 1994 Apr;269(1):7-14. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7909563 # Girard PM, Goldschmidt E, Vittecoq D, Massip P, Gastiaburu J, Meyohas MC, Coulaud JP, Schally AV: Vapreotide, a somatostatin analogue, in cryptosporidiosis and other AIDS-related diarrhoeal diseases. AIDS. 1992 Jul;6(7):715-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1354449 # Stiefel F, Morant R: Vapreotide, a new somatostatin analogue in the palliative management of obstructive ileus in advanced cancer. Support Care Cancer. 1993 Jan;1(1):57-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7511473 # Betoin F, Eschalier A, Duchene-Marullaz P, Lavarenne J: Seven-day antinociceptive effect of a sustained release vapreotide formulation. Neuroreport. 1994 Jan 31;5(5):642-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7912964"@en . "Vapreotide is a synthetic octapeptide somatostatin analog. It was being studied for the treatment of cancer."@en . . . "Vapreotida"@en . . . . . "Vapreotidum"@en . " "@en . "Venkata Raghavendra Palle, Maheedhara Reddy Challa, \"PROCESS FOR PREPARING VAPREOTIDE.\" U.S. Patent US20070111930, issued May 17, 2007."@en . . . . . . "investigational"@en . . "103222-11-3"@en .